Therapeutic potential of directed tyrosine kinase inhibitor therapy in sarcomas

Cancer Control

Volumn 15, Issue 1, 2008, Pages 47-54

  Shor, Audrey C ^a   Agresta, Samuel V ^a   D'Amato, Gina Z ^a   Sondak, Vernon K ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 5,6,7,13 TETRAHYDRO 12 (3 HYDROXYPROPYL) 9 ISOPROPOXYMETHYLINDENO[2,1 A]PYRROLO[3,4 C]CARBAZOL 5(12H) ONE; 5,6,7,13 TETRAHYDRO 12 (3 HYDROXYPROPYL) 9 ISOPROPOXYMETHYLINDENO[2,1 A]PYRROLO[3,4 C]CARBAZOL 5(12H) ONE DIMETHYLGLYCINE ESTER; ANTIBODY; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CEP 5213; DASATINIB; DOXORUBICIN; ERLOTINIB; GEFITINIB; IMATINIB; IRINOTECAN; NVP AEW 541; PROTEIN TYROSINE KINASE INHIBITOR; SEMAXANIB; SORAFENIB; SUNITINIB; TRASTUZUMAB; UNCLASSIFIED DRUG; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE;

ABDOMINAL TUMOR; ALVEOLAR SOFT PART SARCOMA; ANGIOSARCOMA; ANTINEOPLASTIC ACTIVITY; AUTHOR; CANCER PATIENT; CANCER THERAPY; CELL LINE; CLEAR CELL CARCINOMA; CLINICAL TRIAL; DESMOPLASTIC SMALL ROUND CELL TUMOR; DRUG DOSE ESCALATION; EWING SARCOMA; FIBROSARCOMA; GASTROINTESTINAL STROMAL TUMOR; HUMAN; KAPOSI SARCOMA; LUNG METASTASIS; MALIGNANT FIBROUS HISTIOCYTOMA; METASTASIS; MUTATION; MYXOSARCOMA; NEUROFIBROSARCOMA; NONHUMAN; OSTEOSARCOMA; PROTEIN EXPRESSION; REVIEW; RHABDOMYOSARCOMA; SOFT TISSUE SARCOMA; SYNOVIAL SARCOMA; ANIMAL; DRUG EFFECT; ENZYMOLOGY; METABOLISM; SARCOMA;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; SARCOMA;

EID: 40749125333     PISSN: 10732748     EISSN: 15262359     Source Type: Journal    
DOI: 10.1177/107327480801500106     Document Type: Review

References (62)

1. United States Cancer Statistics: 1999-2003 Incidence and Mortality. US Dept of Health and Human Services, December 2006. http://www.cdc.gov/cancer/ npcr/npcrpdfs/US_Cancer_Statistics_2003_Incidence_and_Mortality.pdf. Accessed November 5, 2007.
2. Albritton KH. Sarcomas in adolescents and young adults. Hematol Oncol Clin North Am. 2005;19:527-546, vii.
3. Bleyer WA, Montello M, Budd T, et al. National survival trends of young adults with sarcoma: lack of progress is associated with lack of clinical trial participation. Cancer. 2005;103:1891-1897.
4. Bleyer WA. The adolescent gap in cancer treatment. J Regist Manage. 1996;23:114-115.
5. Bleyer WA, Tejeda H, Murphy SB, et al. National cancer clinical trials: children have equal access; adolescents do not. J Adolesc Health. 1997;21:366-373.
6. Bleyer A, Montello M, Budd T, et al. National survival trends of young adults with sarcoma: lack of progress is associated with lack of clinical trial participation. Cancer. 2005;103:1891-1897.
7. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin. 2004;54:8-29.
8. Chugh R, Thomas D, Wathen K, et al. Imatinib mesylate in soft tissue and bone sarcomas: Interim results of a Sarcoma Alliance for Research thru Collaboration (SARC) phase II trial. J Clin Oncol. 2004;22(14S July 15 suppl):9001. Abstract.
9. Morgan J. Durable responses to SU11248 (sunitinib malate) are observed across all genotypes of imatinib mesylate-resistant GIST. Presented at the 17th International Congress on Anti-Cancer Treatment. January 2006; Paris, France.
10. Helman LJ, Meltzer P. Mechanisms of sarcoma development. Nat Rev Cancer. 2003;3:685-694.
11. Nichols GL. Tyrosine kinase inhibitors as cancer therapy. Cancer Invest. 2003;21:758-771.
12. van Oosterom AT, Judson I, Verweij J, et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet. 2001;358:1421-1423.
13. McArthur GA, Demetri GD, van Oosterom A, et al. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. J Clin Oncol. 2005;23:866-873.
14. Blanke CD, Eisenberg BL, Heinrich MC. Gastrointestinal stromal tumors. Curr Treat Options Oncol. 2001;2:485-491.
15. DeMatteo RP, Lewis JJ, Leung D, et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg. 2000;231:51-58.
16. Duensing A, Heinrich MC, Fletcher CD, et al. Biology of gastrointestinal stromal tumors: KIT mutations and beyond. Cancer Invest. 2004;22:106-116.
17. Goss G, Merriam P, Manola J, et al. Clinical and pathological characteristics of gastrointestinal stromal tumors (GISTs). Proc Annu Meet Am Soc Clin Oncol. 2000;19:2203. Abstract.
18. Heinrich M, Corless C, Blanke C, et al. KIT mutational status predicts clinical response to STI571 in patients with metastatic gastrointestinal stromal tumors (GISTs). Proc Annu Meet Am Soc Clin Oncol. 2002;21:6. Abstract.
19. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med. 2001;344:1052-1056.
20. Schindler CG, Armbrust T, Gunawan B, et al. Gastrointestinal stromal tumor (GIST): single center experience of prolonged treatment with imatinib. Z Gastroenterol. 2005;43:267-273.
21. Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet. 2004;364:1127-1134.
22. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472-480.
23. Joensuu H. Gastrointestinal stromal tumor (GIST). Ann Oncol. 2006;17:x280-x286.
24. Rubin BP, Singer S, Tsao C, et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res. 2001;61:8118-8121.
25. Koon HB, Bubley GJ, Pantanowitz L, et al. Imatinib-induced regression of AIDS-related Kaposi's sarcoma. J Clin Oncol. 2005;23:982-989. Epub 2004 Nov 30
26. Scotlandi K, Manara MC, Strammiello R, et al. C-kit receptor expression in Ewing's sarcoma: lack of prognostic value but therapeutic targeting opportunities in appropriate conditions. J Clin Oncol. 2003;21:1952-1960.
27. Merchant MS, Woo CW, Mackall CL, et al. Potential use of imatinib in Ewing's Sarcoma: evidence for in vitro and in vivo activity. J Natl Cancer Inst. 2002;94:1673-1679.
28. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031-1037.
29. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001;344:1038-1042. Erratum in: N Engl J Med. 2001;345:232.
30. Peng B, Hayes M, Racine-Poon A, et al. Clinical investigation of the pharmacokinetic/pharmacodynamic relationship for Glivec (STI571): a novel inhibitor of signal transduction. Proc Annu Meet Am Soc Clin Oncol. 2001;20:280a. Abstract.
31. Druker BJ. Taking aim at Ewing's sarcoma: is KIT a target and will imatinib work? J Natl Cancer Inst. 2002;94:1660-1661.
32. Yoshitani K, Honoki K, Morishita T, et al. Growth inhibition of rat osteosarcoma and malignant fibrous histiocytoma cells by tyrosine kinase inhibitor STI571. In Vivo. 2003;17:255-258.
33. McGary EC, Weber K, Mills L, et al. Inhibition of platelet-derived growth factor-mediated proliferation of osteosarcoma cells by the novel tyrosine kinase inhibitor STI571. Clin Cancer Res. 2002;8:3584-3591.
34. Matsuyama S, Iwadate M, Kondo M, et al. SB-431542 and Gleevec inhibit transforming growth factor-beta-induced proliferation of human osteosarcoma cells. Cancer Res. 2003;63:7791-7798.
35. Greco A, Roccato E, Miranda C, et al. Growth-inhibitory effect of STI571 on cells transformed by the COL1A1/PDGFB rearrangement. Int J Cancer. 2001;92:354-360.
36. Hotfilder M, Lanvers C, Jürgens H, et al. c-KIT-expressing Ewing tumour cells are insensitive to imatinib mesylate (STI571). Cancer Chemother Pharmacol. 2002;50:167-169.
37. Stewart CF, Leggas M, Schuetz JD, et al. Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice. Cancer Res. 2004;64:7491-7499.
38. Kuenen BC, Tabernero J, Baselga J, et al. Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma. Clin Cancer Res. 2003;9:1648-1655.
39. Angelov L, Salhia B, Roncari L, et al. Inhibition of angiogenesis by blocking activation of the vascular endothelial growth factor receptor 2 leads to decreased growth of neurogenic sarcomas. Cancer Res. 1999;59:5536-5541.
40. Dalal S, Berry AM, Cullinane CJ, et al. Vascular endothelial growth factor: a therapeutic target for tumors of the Ewing's sarcoma family. Clin Cancer Res. 2005;11:2364-2378.
41. Gingrich DE, Reddy DR, Iqbal MA, et al. A new class of potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: structure-activity relationships for a series of 9-alkoxymethyl-12-(3- hydroxypropyl) indeno[2,1-a]pyrrolo[3,4-c]carbazole-5-ones and the identification of CEP-5214 and its dimethylglycine ester prodrug clinical candidate CEP-7055. J Med Chem. 2003;46:5375-5388.
42. Scotlandi K, Manara MC, Nicoletti G, et al. Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. Cancer Res. 2005;65:3868-3876.
43. Shor AC, Keschman EA, Lee FY, et al. Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on Src kinase for survival. Cancer Res. 2007;67:2800-2808.
44. Balasubramanian L, Evens AM. Targeting angiogenesis for the treatment of sarcoma. Curr Opin Oncol. 2006;18:354-359.
45. Ye D, Maitra A, Timmons CF, et al. The epidermal growth factor receptor HER2 is not a major therapeutic target in Ewing sarcoma. J Pediatr Hematol Oncol. 2003;25:459-466.
46. Guan H, Jia SF, Zhou Z, et al. Herceptin down-regulates HER-2/neu and vascular endothelial growth factor expression and enhances taxol-induced cytotoxicity of human Ewing's sarcoma cells in vitro and in vivo. Clin Cancer Res. 2005;11:2008-2017.
47. D'Adamo DR, Anderson SE, Albritton K, et al. Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. J Clin Oncol. 2005;23:7135-7142.
48. Azizi AA, Haberler C, Czech T, et al. Vascular-endothelial-growth-factor (VEGF) expression and possible response to angiogenesis inhibitor bevacizumab in metastatic alveolar soft part sarcoma. Lancet Oncol. 2006;7:521-523.
49. Bond M, Bernstein ML, Pappo A, et al. A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children's Oncology Group study. Pediatr Blood Cancer. 2007 Jan 29. Epub ahead of print.
50. Sato O, Wada T, Kawai A, et al. Expression of epidermal growth factor receptor, ERBB2 and KIT in adult soft tissue sarcomas: a clinicopathologic study of 281 cases. Cancer. 2005;103:1881-1890.
51. Daw NC, Furman WL, Stewart CF, et al. Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol. 2005;23:6172-6180.
52. Scotlandi K, Manara MC, Hattinger CM, et al. Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing's sarcoma. Eur J Cancer. 2005;41:1349-1361.
53. Akatsuka T, Wada T, Kokai Y, et al. ErbB2 expression is correlated with increased survival of patients with osteosarcoma. Cancer 2002;94:1397-1404.
54. Hughes DP, Thomas DG, Giordano TJ, et al. Cell surface expression of epidermal growth factor receptor and Her-2 with nuclear expression of Her-4 in primary osteosarcoma. Cancer Res. 2004;64:2047-2053.
55. Thomas DG, Giordano TJ, Sanders D, et al. Expression of receptor tyrosine kinases epidermal growth factor receptor and HER-2/neu in synovial sarcoma. Cancer. 2005;103:830-838.
56. Ahlén J, Wejde J, Brosjö O, et al. Insulin-like growth factor type 1 receptor expression correlates to good prognosis in highly malignant soft tissue sarcoma. Clin Cancer Res. 2005;11:206-216.
57. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64:7099-7109.
58. Chang YS, Adnane J, Trail PA, et al. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol. 2007;59:561-574. Epub 2006 Dec 8.
59. Rodriguez-Viciana P, Tetsu O, Oda K, et al. Cancer targets in the Ras pathway. Cold Spring Harb Symp Quant Biol. 2005;70:461-467.
60. Adnane L, Trail PA, Taylor I, et al. Sorafenib (BAY 43-9006, Nexavar®, a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol. 2005;407:597-612.
61. Guida T, Anaganti S, Provitera L, et al. Sorafenib inhibits imatinib-resistant KIT and platelet-derived growth factor receptor beta gatekeeper mutants. Clin Cancer Res. 2007;13:3363-3369.
62. D'Adamo DR, Keohan M, Schuetze S, et al. Clinical results of a phase II study of sorafenib in patients (pts) with non-GIST sarcomas (CTEP study #7060). J Clin Oncol. 2007;25(18S June 20 suppl):10001. Abstract.